Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.54 |
| ▸ | BCHE | P06276 | 11/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802669 | 0.88 | MEN1 (0.46) | ACHEBCHEFAAHMTORMARK4 | |
| SCHEMBL1520362 | 0.83 | MTOR (0.62) | MTORMEN1MAPTCYP2C9KMT2A | |
| Benzene SCHEMBL28986126 | 0.83 | MTOR (0.62) | MTORMEN1MAPTCYP2C9KMT2A | |
| SCHEMBL3629562 | 0.79 | ACHE (0.51) | ACHEBCHEFAAHMTORMARK4 | |
| SCHEMBL1561077 | 0.77 | ACHE (0.49) | ACHEBCHEFAAHMARK4MEN1 | |
| SCHEMBL1561101 | 0.77 | ACHE (0.49) | ACHEBCHEFAAHMARK4MEN1 | |
| SCHEMBL24222513 | 0.77 | ACHE (0.50) | ACHEBCHEFAAHMARK4MEN1 | |
| SCHEMBL8201572 | 0.75 | ACHE (0.75) | ACHEBCHEFAAHMARK4ALOX5 | |
| SCHEMBL8191585 | 0.75 | ACHE (0.75) | ACHEBCHEFAAHMARK4ALOX5 | |
| SCHEMBL3891099 | 0.74 | ACHE (0.52) | ACHEBCHEFAAHMARK4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637713-B2 | Process for preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | claimed |
| US-8415508-B2 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | claimed |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| EP-2711354-B1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | ZHEJIANG HISUN PHARM CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| US-9353049-B2 | Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2016-05-31 | — | — | US | disclosed |
| EP-2711354-A1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2014-03-26 | — | — | EP | disclosed |
| US-20140073809-A1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | SPR, ACHE, QDPR | ACHE 2/4885BCHE 33/4885FAAH 760/4885 |
| US-20140073809-A1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | ACHE, PSEN1, CHRM5 | ACHE 1/4885BCHE 8/4885FAAH 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.